A board certified neurologist with specialty training in neuro-oncology, Dr. Nimish Mohile completed his residency in neurology at Northwestern University followed by a fellowship in neuro-oncology at Memorial Sloan-Kettering Cancer Center. Dr. Mohile joined the faculty at the University of Rochester in 2007 where he has a joint appointment in neurology and oncology. He sees patients at the James P. Wilmot Cancer Center and at Strong Memorial Hospital.

Dr. Mohile sees patients with primary and metastatic brain tumors and is involved in administering chemotherapy, treating seizures and managing side effects of brain tumors and brain tumor therapy. In addition, he does consultations on patients with neurologic complications of cancer or cancer treatments.
His research focuses on understanding the role of cancer stem cells in the progression of brain tumors. He is interested in developing novel therapies for the treatment of all types of brain tumors and is currently the principal investigator of several clinical trials at the University of Rochester.

Publications:

Gewandter JS, Dworkin RH, Finnerup NB, Mohile NA. "Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?" Pain.. 2017 158(1):30-33.

Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J. "A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma." CNS oncology.. 2017 6(1):29-43. Epub 2016 Sep 15.

Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ. "Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2016 Sep 0; 16(9):e123-e127. Epub 2016 Jun 08.

View All Publications